Why randomized trials for proton therapy are difficult to complete (and what we can do about it)

(University of Pennsylvania School of Medicine) Commercial insurance medical policies that do not cover treatment with proton therapy can make it difficult for patients to participate in randomized clinical trials funded by the NCI, part of the National Institutes of Health, that are evaluating the therapy.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news

Related Links:

[Image from unsplash.com]Venture capital firms invested more than $2.9 billion in medical device companies in 2018 — a slight increase from the $2.8 billion raised in 2017, according to the MoneyTree report from PricewaterhouseCoopers (PwC) and CB Insights. Both the first and second quarters of 2018 saw an increase in investments, totaling nearly $778 million and $786 million respectively. The third and fourth quarters were slightly lower, with medtech companies raising $738 million in Q3 and nearly $641 million in Q4. There were 218 deals in 2018, a slight decrease from the 229 deals involving me...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News venture capital Source Type: news
This study determines the impact of change in aeration in sinonasal cavities on the robustness of passive-scattering proton therapy plans in patients with sinonasal and nasopharyngeal malignancies. Fourteen patients, each with one planning CT and one CT acquired during radiotherapy were studied. Repeat and planning CTs were rigidly aligned and contours were transferred using deformable registration. The amount of air, tumor, and fluid within the cavity containing the tumor were measured on both CTs. The original plans were recalculated on the repeat CT. Dosimetric changes were measured for the targets and critical structur...
Source: Journal of Applied Clinical Medical Physics - Category: Physics Authors: Tags: J Appl Clin Med Phys Source Type: research
PMID: 30735613 [PubMed - as supplied by publisher]
Source: Journal of Applied Clinical Medical Physics - Category: Physics Authors: Tags: J Appl Clin Med Phys Source Type: research
Time-resolved volumetric magnetic resonance imaging (4DMRI) offers the potential to analyze 3D motion with high soft-tissue contrast without additional imaging dose. We use 4DMRI to investigate the interplay e...
Source: Radiation Oncology - Category: Cancer & Oncology Authors: Tags: Research Source Type: research
We present the largest ever population of patients with neuroblastoma treated with proton therapy, demonstrating minimal toxicity and 97% local disease free survival. This treatment is safe and allows minimization of dose to normal tissues in young patients with neuroblastoma, who require intensive multimodality therapy.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Clinical Investigation Source Type: research
AbstractCranio-spinal irradiation (CSI) is widely used for treating medulloblastoma cases in children. Radiation-induced second malignancy is of grave concern; especially in children due to their long-life expectancy and higher radiosensitivity of tissues at young age. Several techniques can be employed for CSI including 3DCRT, IMRT, VMAT and tomotherapy. However, these techniques are associated with higher risk of second malignancy due to the physical characteristics of photon irradiation which deliver moderately higher doses to normal tissues. On the other hand, proton beam therapy delivers substantially lesser dose to n...
Source: Australasian Physical and Engineering Sciences in Medicine - Category: Biomedical Engineering Source Type: research
Condition:   Tonsil Cancer Intervention:   Radiation: Radiotherapy Sponsor:   Lund University Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
In this 13-month-old girl with anaplastic ependymoma, biopsy of the suspicious mass is strongly recommended because treatment varies significantly if the disease has metastasized.1 If this mass is benign, we recommend radiation to the primary tumor bed with 5  mm clinical target volume and 3 mm planning target volume margins using proton therapy to a total dose of 54 Gy (relative biological effectiveness) (Fig. 1). If the spinal disease is biopsy-proven metastatic ependymoma, there are several options, though none ideal.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Gray Zone Source Type: research
Abstract Proton transmission imaging has been proposed and investigated as imaging modality complementary to X-ray based techniques in proton beam therapy. In particular, it addresses the issue of range uncertainties due to the conversion of an X-ray patient computed tomography (CT) image expressed in Hounsfield Units (HU) to relative stopping power (RSP) needed as input to the treatment planning system. One approach to exploit a single proton radiographic projection is to perform a patient-specific calibration of the CT to RSP conversion curve by optimising the match between a measured and a numerically integrate...
Source: Physics in Medicine and Biology - Category: Physics Authors: Tags: Phys Med Biol Source Type: research
More News: Clinical Trials | Insurance | International Medicine & Public Health | National Institutes of Health (NIH) | Proton Therapy | University of Pennsylvania